KRAS and non-small cell lung carcinoma: In a study investigating the impact of six SWI/SNF genes, including SMARCA4, on immunotherapy (e.g., CTLA4 and PD-1 inhibitors) outcomes in KRAS-mutant NSCLC, the worst OS and prognosis was associated with SMARCA4 mutants, indicating the unfortunate outcome of this gene alteration with KRAS [137].